251 related articles for article (PubMed ID: 17598435)
21. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
[TBL] [Abstract][Full Text] [Related]
22. Acetylation phenotype is not associated with breast cancer.
Ilett KF; Detchon P; Ingram DM; Castleden WM
Cancer Res; 1990 Oct; 50(20):6649-51. PubMed ID: 2208127
[TBL] [Abstract][Full Text] [Related]
23. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
[TBL] [Abstract][Full Text] [Related]
24. Acetylation phenotype in colorectal carcinoma.
Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
[TBL] [Abstract][Full Text] [Related]
25. [Acetylation polymorphism in lung cancer].
Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
[TBL] [Abstract][Full Text] [Related]
26. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
Kaneko K; Atsumi T; Miyataka T
Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
[TBL] [Abstract][Full Text] [Related]
27. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
[TBL] [Abstract][Full Text] [Related]
28. Incidence of isoniazid acetylation phenotypes in North Indians.
Gupta RC; Nair CR; Jindal SK; Malik SK
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
[TBL] [Abstract][Full Text] [Related]
29. The acetylation and oxidation phenotypes in insulin-dependent diabetes mellitus.
Mrozikiewicz A; Kiełczewska-Mrozikiewicz D; Lowicki Z; Chmara E; Mrozikiewicz PM; Jabłecka A; Kaźmierczak E; Andrys I
Mater Med Pol; 1995; 27(4):147-9. PubMed ID: 9000838
[TBL] [Abstract][Full Text] [Related]
30. N-acetylator phenotypes in hyperthyroidism.
Siegmund W; Franke G; Meng S; Gothe P; Meng W
Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):397-9. PubMed ID: 3220615
[TBL] [Abstract][Full Text] [Related]
31. Polymorphism of dextromethorphan oxidation in Polish population.
Skretkowicz J; Wojtczak A; Rychlik-Sych M
Acta Pol Pharm; 2008; 65(5):611-5. PubMed ID: 19051610
[TBL] [Abstract][Full Text] [Related]
32. Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers.
Augustynowicz-Kopeć E; Zwolska Z
Acta Pol Pharm; 2002; 59(6):452-7. PubMed ID: 12669770
[TBL] [Abstract][Full Text] [Related]
33. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
[TBL] [Abstract][Full Text] [Related]
34. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
[TBL] [Abstract][Full Text] [Related]
35. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
[TBL] [Abstract][Full Text] [Related]
36. Acetylation phenotypes in patients with bladder carcinoma.
Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
[TBL] [Abstract][Full Text] [Related]
37. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
Singh SP; Pande JN; Khilnani GC; Kailash S
Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
[TBL] [Abstract][Full Text] [Related]
38. Sulphamethoxazole acetylation in fast and slow acetylators.
Bozkurt A; Basci NE; Isimer A; Tuncer M; Erdal R; Kayaalp SO
Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):164-6. PubMed ID: 2338369
[TBL] [Abstract][Full Text] [Related]
39. Acetylation phenotype and skin complexion.
Rampen FH; van der Meeren HL; Stolk LM
Acta Derm Venereol; 1986; 66(4):334-6. PubMed ID: 2430405
[TBL] [Abstract][Full Text] [Related]
40. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
